Impairment of hemostasis in patients with severe hemophilia. Failure of diphenhydramine, chlorpromazine, and guaifenesin

G. R. Buchanan, R. I. Handin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Twenty-three patients with severe hemophilia were given single or multiple doses of diphenhydramine hydrochloride, chlorpromazine hydrochloride, or guaifenesin to test their effects on hemostatis. In contrast with earlier studies with aspirin, bleeding times were not prolonged after ingestion of these drugs. No patient had hemorrhage because of the drugs, and none recalled excessive bleeding following drug ingestion. These results greatly extend the clinical implications of prior observations carried out in normal subjects demonstrating that many antiplatelet drugs have no effects on in vivo hemostatis. We conclude that these drugs are probably safe for patients with bleeding disorders like hemophilia

Original languageEnglish (US)
Pages (from-to)2173-2174
Number of pages2
JournalJournal of the American Medical Association
Volume240
Issue number20
DOIs
StatePublished - 1978

Fingerprint

Guaifenesin
Diphenhydramine
Chlorpromazine
Hemophilia A
Hemostasis
Hemorrhage
Pharmaceutical Preparations
Eating
Bleeding Time
Platelet Aggregation Inhibitors
Aspirin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{fd70b273856c44b7b6cb0fea876c8e61,
title = "Impairment of hemostasis in patients with severe hemophilia. Failure of diphenhydramine, chlorpromazine, and guaifenesin",
abstract = "Twenty-three patients with severe hemophilia were given single or multiple doses of diphenhydramine hydrochloride, chlorpromazine hydrochloride, or guaifenesin to test their effects on hemostatis. In contrast with earlier studies with aspirin, bleeding times were not prolonged after ingestion of these drugs. No patient had hemorrhage because of the drugs, and none recalled excessive bleeding following drug ingestion. These results greatly extend the clinical implications of prior observations carried out in normal subjects demonstrating that many antiplatelet drugs have no effects on in vivo hemostatis. We conclude that these drugs are probably safe for patients with bleeding disorders like hemophilia",
author = "Buchanan, {G. R.} and Handin, {R. I.}",
year = "1978",
doi = "10.1001/jama.240.20.2173",
language = "English (US)",
volume = "240",
pages = "2173--2174",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "20",

}

TY - JOUR

T1 - Impairment of hemostasis in patients with severe hemophilia. Failure of diphenhydramine, chlorpromazine, and guaifenesin

AU - Buchanan, G. R.

AU - Handin, R. I.

PY - 1978

Y1 - 1978

N2 - Twenty-three patients with severe hemophilia were given single or multiple doses of diphenhydramine hydrochloride, chlorpromazine hydrochloride, or guaifenesin to test their effects on hemostatis. In contrast with earlier studies with aspirin, bleeding times were not prolonged after ingestion of these drugs. No patient had hemorrhage because of the drugs, and none recalled excessive bleeding following drug ingestion. These results greatly extend the clinical implications of prior observations carried out in normal subjects demonstrating that many antiplatelet drugs have no effects on in vivo hemostatis. We conclude that these drugs are probably safe for patients with bleeding disorders like hemophilia

AB - Twenty-three patients with severe hemophilia were given single or multiple doses of diphenhydramine hydrochloride, chlorpromazine hydrochloride, or guaifenesin to test their effects on hemostatis. In contrast with earlier studies with aspirin, bleeding times were not prolonged after ingestion of these drugs. No patient had hemorrhage because of the drugs, and none recalled excessive bleeding following drug ingestion. These results greatly extend the clinical implications of prior observations carried out in normal subjects demonstrating that many antiplatelet drugs have no effects on in vivo hemostatis. We conclude that these drugs are probably safe for patients with bleeding disorders like hemophilia

UR - http://www.scopus.com/inward/record.url?scp=0018135444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018135444&partnerID=8YFLogxK

U2 - 10.1001/jama.240.20.2173

DO - 10.1001/jama.240.20.2173

M3 - Article

C2 - 702728

AN - SCOPUS:0018135444

VL - 240

SP - 2173

EP - 2174

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 20

ER -